Search Results - "Curti, B D"

Alterations in T cell receptor and signal transduction molecules in melanoma patients by ZEA, A. H, CURTI, B. D, OCHOA, A. C, LONGO, D. L, ALVORD, W. G, STROBL, S. L, MIZOGUCHI, H, CREEKMORE, S. P, O'SHEA, J. J, POWERS, G. C, URBA, W. J

“…We have recently described molecular changes in T cells from tumor-bearing patients that are associated with depressed immune function. The present work…”
Get full text

Initial cohort expansion results of sustained arginine depletion with pegzilarginase in melanoma patients in a phase I advanced solid tumor trial by Chmielowski, B., Gordon, M., Buchbinder, E.I., Sullivan, R.J., Cohen, J.V., Curti, B.D., Davar, D., Homsi, J., Komatsubara, K.M., Lara-Guerra, H., Alters, S.E., Ferrati, S., Eckert, S., Rowlinson, S.W., Wooldridge, J.E., Ribas, A., Carvajal, R.D.

Get full text

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients by Rudin, C.M., Pandha, H.S., Gupta, S., Zibelman, M.R., Akerley, W., Day, D., Hill, A.G., Sanborn, R.E., O'Day, S.J., Clay, T.D., Wright, G.M., Jennens, R., Gerber, D.E., Rosenberg, J.E., Ralph, C., Campbell, D.C., Curti, B.D., Schmidt, E.V., Grose, M., Shafren, D.

Get full text

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies by Smith, 2nd, J W, Urba, W J, Curti, B D, Elwood, L J, Steis, R G, Janik, J E, Sharfman, W H, Miller, L L, Fenton, R G, Conlon, K C

“…A phase I trial was undertaken because interleukin-1 alpha (IL-1 alpha) possesses antiproliferative, immunostimulatory, antiinfection, myeloprotective, and…”
Get more information

Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer by Curti, B D, Ochoa, A C, Powers, G C, Kopp, W C, Alvord, W G, Janik, J E, Gause, B L, Dunn, B, Kopreski, M S, Fenton, R, Zea, A, Dansky-Ullmann, C, Strobl, S, Harvey, L, Nelson, E, Sznol, M, Longo, D L

“…We performed a phase I trial to determine whether in vivo expansion of activated CD4+ T cells was possible in cancer patients. 111Indium labeling was used to…”
Get more information

Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients : changes during treatment by CURTI, B. D, URBA, W. J, ALVORD, W. G, JANIK, J. E, SMITH, J. W, MADARA, K, LONGO, D. L

“…Interstitial pressure (IP) is a physiological variable that may have its greatest influence on the transport of high-molecular-weight therapeutic agents. IP in…”
Get full text

Hepatobiliary lymphoepithelioma-like carcinoma associated with Epstein-Barr virus by VORTMEYER, A. O, KINGMA, D. W, FENTON, R. G, CURTI, B. D, JAFFE, E. S, DURAY, P. H

“…We describe the clinical and pathologic features of a lymphoepithelioma-like carcinoma (LELC) that originated in the hepatobiliary system. A woman, aged 71…”
Get full text

The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin by Smith, John W, Longo, Dan L, Alvord, W. Gregory, Janik, John E, Sharfman, William H, Gause, Barry L, Curti, Brendan D, Creekmore, Stephen P, Holmlund, Jon T, Fenton, Robert G, Sznol, Mario, Miller, Langdon L, Shimizu, Masanao, Oppenheim, Joost J, Fiem, Shelby J, Hursey, Jean C, Powers, Gerry C, Urba, Walter J

“…Escalation of the dose of many antineoplastic drugs is limited by granulocytopenia and thrombocytopenia. Although colony-stimulating factors 1 , 2 and the…”
Get full text

Abrogation of the Hematological and Biological Activities of the Interleukin-3/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein PIXY321 by Neutralizing Anti-PIXY321 Antibodies in Cancer Patients Receiving High-Dose Carboplatin by Miller, Langdon L., Korn, Edward L., Stevens, Diane S., Janik, John E., Gause, Barry L., Kopp, William C., Holmlund, Jon T., Curti, Brendan D., Sznol, Mario, Smith, John W., Urba, Walter J., Donegan, Sarah E., Watson, Thelma M., Longo, Dan L.

“…This dose-escalation study was performed to evaluate the hematologic activity, biological effects, immunogenicity, and toxicity of PIXY321 (an…”
Get full text

Treatment with Tumor Necrosis Factor-α and Granulocyte–Macrophage Colony-Stimulating Factor Increases Epidermal Langerhans' Cell Numbers in Cancer Patients by Janik, John E., Miller, Langdon L., Kopp, William C., Taub, Dennis D., Dawson, Harry, Stevens, Diane, Kostboth, Paige, Curti, Brendan D., Conlon, Kevin C., Dunn, Barbara K., Donegan, Sarah E., Ullrich, Robert, Alvord, W.Gregory, Gause, Barry L., Longo, Dan L.

“…Dendritic cells (DCs) initiate primary and stimulate secondary T-cell responses. We conducted a phase I trial of tumor necrosis factor (TNF-α) and…”
Get full text

Phase II Trial of Interleukin 1α and Indomethacin in Treatment of Metastatic Melanoma by Janik, John E., Miller, Langdon L., Longo, Dan L., Powers, Geraldine C., Urba, Walter J., Kopp, William C., Gause, Barry L., Curti, Brendan D., Fenton, Robert G., Oppenheim, Joost J., Conlon, Kevin C., Holmlund, Jon T., Sznol, Mario, Sharfman, William H., Steis, Ronald G., Creekmore, Stephen P., Alvord, W. Gregory, Beauchamp, Ann E., Smith, John W.

“…Background: The rising incidence of malignant melanoma and the lack of curative therapies for metastatic disease represent a therapeutic challenge. New agents…”
Get full text

Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2 by Curti, B D, Longo, D L, Ochoa, A C, Conlon, K C, Smith, 2nd, J W, Alvord, W G, Creekmore, S P, Fenton, R G, Gause, B L, Holmlund, J

“…This study describes the physiologic and biologic effects resulting from the adoptive transfer of ex vivo anti-CD3-stimulated T-killer cells (T-AK) to patients…”
Get more information

Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity by SAXTON, M. L, LONGO, D. L, WETZEL, H. E, TRIBBLE, H, ALVORD, W. G, KWAK, L. W, LEONARD, A. S, ULLMANN, C. D, CURTI, B. D, OCHOA, A. C

“…The infusion of anti-CD3-activated murine T cells plus interleukin-2 (IL-2) exerts antitumor effects against several tumors in murine immunotherapy models…”
Get full text

Physical barriers to drug delivery in tumors by Curti, B D

Get more information

A phase II study of carboplatin, cisplatin, interferon-α, and tamoxifen for patients with metastatic melanoma by GAUSE, B. L, SHARFMAN, W. H, JANIK, J. E, CURTI, B. D, RONALD, STEIS, G, URBA, W. J, SMITH, J. W, ALVORD, W. G, ONGO, D. L

“…The purpose of this trial was to determine the toxicity and antineoplastic activity of cisplatin, carboplatin, tamoxifen, and interferon-alpha (IFN-alpha) in…”
Get full text

Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients by Curti, B D, Ochoa, A C, Urba, W J, Alvord, W G, Kopp, W C, Powers, G, Hawk, C, Creekmore, S P, Gause, B L, Janik, J E, Holmlund, J T, Kremers, P, Fenton, R G, Miller, L, Sznol, M, Smith, 2nd, J W, Sharfman, W H, Longo, D L

“…The adoptive transfer of anti-CD3-stimulated T killer (T-AK) cells was tested with different bolus and infusional interleukin-2 (IL-2) regimens, and anti-CD3…”
Get more information

Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer by Curti, B D, Urba, W J, Longo, D L, Janik, J E, Sharfman, W H, Miller, L L, Cizza, G, Shimizu, M, Oppenheim, J J, Alvord, W G, Smith, 2nd, J W

“…Previous primate and rodent studies suggested that interleukin-1 alpha (IL-1 alpha) caused changes in the secretion of pituitary, adrenal, thyroid, and gonadal…”
Get more information

A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma by Fenton, R G, Steis, R G, Madara, K, Zea, A H, Ochoa, A C, Janik, J E, Smith, 2nd, J W, Gause, B L, Sharfman, W H, Urba, W J, Hanna, M G, DeJager, R L, Coyne, M X, Crouch, R D, Gray, P, Beveridge, J, Creekmore, S P, Holmlund, J, Curti, B D, Sznol, M, Longo, D L

“…We performed a prospective, randomized study to determine whether subcutaneous administration of interleukin-2 (IL-2) in combination with an autologous renal…”
Get more information

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses by Seung, Steven K, Curti, Brendan D, Crittenden, Marka, Walker, Edwin, Coffey, Todd, Siebert, Janet C, Miller, William, Payne, Roxanne, Glenn, Lyn, Bageac, Alexandru, Urba, Walter J

“…Preclinical models suggest that focal high-dose radiation can make tumors more immunogenic. We performed a pilot study of stereotactic body radiation therapy…”
Get more information

Adoptive immunotherapy by Curti, B D

Get more information